Prof. Dirk Arnold


Professor of Oncology, Director of Asklepios

Tumorzentrum Hamburg, and chairman of

the Department for Oncology, Hematology

and Rheumatology at AK Alton, Hamburg.


Saturday 4-5-2024 Day 2

Pancreatic cancer

  • Neoadjuvant therapy in resectable/borderline resectable pancreatic cancer
  • Best neoadjuvant strategy
  • 1st line and subsequent therapies in pancreatic cancer: Doublet vs Triplets
  • biomarkers for metastatic patients

Moderator: Dr. Abdullah Alsharm



Saturday 4-5-2024 Day 2

Perioperative therapy in Gastric cancer

  • Role of laparoscopy assessment before perioperative therapy?
  • What to do in patients with poor response to neoadjuvant therapy?
  • Role of biomarkers e.g MSI in decision-making before perioperative therapy?
  • Patients with limited peritoneal metastasis: Role of HIPEC?
  • Role of immunetherapy with perioperative therapy non-metastatic gastric cancer?

Moderator:  Dr. Fahad Ibnshamsah


Saturday 4-5-2024 Day 2

Immunetherapy in CRC: Transition from metastatic to early stage